All 3 dose levels of the malaria vaccine
elicited high levels of antibodies recognizing the vaccine antigen after a single immunization, peaking a month after the third immunization.
Not exact matches
In fact, the vaccine used in the VAX003 trial actually
elicited higher levels of most
of the
antibodies than the prime / boost combination
of the more successful RV144 trial.
Our proprietary TheraT ® and Vaxwave ® platforms have shown promising abilities to
elicit high neutralizing
antibody responses, but also necessary
levels of T cell responses, currently missing in most vaccine and therapeutic approaches.